Catalysts / ATTO
Upcoming FDA decisions and readouts we track for Attovia Therapeutics, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Attovia Therapeutics (ATTO, listed on Nasdaq). It concerns ATTO-1310 (Chronic pruritus and high-itch atopic dermatitis (IL-31)).
First on the list: the Phase 1B readout for ATTO-1310 (Chronic pruritus and high-itch atopic dermatitis (IL-31)), guided by the company to Q4 2026.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Attovia Therapeutics ATTO · Nasdaq | ATTO-1310 | Chronic pruritus and high-itch atopic dermatitis (IL-31) | Q4 2026 company guidance |
Phase 1B readout | Verified | 8-K exhibit 99.1 ↗ | No |
FreeBioList